Effect of Coadministration of Moxifloxacin and Rifampin on Mycobacterium tuberculosis in a Murine Aerosol Infection Model
- 1 June 2012
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 56 (6) , 3054-3057
Abstract
Coadministration of moxifloxacin and rifampin was evaluated in a murine model ofMycobacterium tuberculosispulmonary infection to determine whether the finding of antagonism documented in a hollow-fiber infection model could be recapitulatedin vivo. Colony counts were followed in a no-treatment control group, groups administered moxifloxacin or rifampin monotherapy, and a group administered a combination of the two agents. Following 18 days of once-daily oral administration to mice infected withM. tuberculosis, there was a reduction in the plasma exposure to rifampin that decreased further when rifampin was coadministered with moxifloxacin. Pharmacodynamic analysis demonstrated a mild antagonistic interaction between moxifloxacin and rifampin with respect to cell kill in the mouse model for tuberculosis (TB). No emergence of resistance was noted over 28 days of therapy, even with monotherapy. This was true even though one of the agents in the combination (moxifloxacin) induces error-prone replication. The previously noted antagonism with respect to cell kill shown in the hollow-fiber infection model was recapitulated in the murine TB lung model, although to a lesser extent.Keywords
This publication has 11 references indexed in Scilit:
- Effect of Administration of Moxifloxacin plus Rifampin against Mycobacterium tuberculosis for 7 of 7 Days versus 5 of 7 Days in an In Vitro Pharmacodynamic SystemmBio, 2011
- The Combination of Rifampin plus Moxifloxacin Is Synergistic for Suppression of Resistance but Antagonistic for Cell Kill ofMycobacterium tuberculosisas Determined in a Hollow-Fiber Infection ModelmBio, 2010
- Mycobacterium tuberculosis DNA repair in response to subinhibitory concentrations of ciprofloxacinJournal of Antimicrobial Chemotherapy, 2008
- Concentration-Dependent Mycobacterium tuberculosis Killing and Prevention of Resistance by RifampinAntimicrobial Agents and Chemotherapy, 2007
- Effects of Rifampin and Multidrug Resistance Gene Polymorphism on Concentrations of MoxifloxacinAntimicrobial Agents and Chemotherapy, 2007
- Moxifloxacin, Ofloxacin, Sparfloxacin, and Ciprofloxacin against Mycobacterium tuberculosis : Evaluation of In Vitro and Pharmacodynamic Indices That Best Predict In Vivo EfficacyAntimicrobial Agents and Chemotherapy, 2007
- Emergence of Fluoroquinolone Resistance in Mycobacterium tuberculosis during Continuously Dosed Moxifloxacin Monotherapy in a Mouse ModelAntimicrobial Agents and Chemotherapy, 2005
- Pharmacokinetics-Pharmacodynamics of Rifampin in an Aerosol Infection Model of TuberculosisAntimicrobial Agents and Chemotherapy, 2003
- P-glycoprotein: a major determinant of rifampicin-inducible expression of cytochrome P4503A in mice and humans.Proceedings of the National Academy of Sciences, 1996
- The search for synergy: a critical review from a response surface perspective.Pharmacological Reviews, 1995